Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development.
Department of Psychiatry and Psychology Mayo Clinic Depression Center Mayo Clinic Rochester, MN mfrye@mayo.edu University of Ottawa Institute of Mental Health Research Mood Disorders Research Ottawa, Ontario, Canada Department of Psychiatry and Psychology Mayo Clinic Depression Center Mayo Clinic Rochester, MN.
Mark A
MA
Frye
Pierre
P
Blier
Susannah J
SJ
Tye
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D003863:Depression / Q000188:drug therapy*; D061218:Depressive Disorder, Treatment-Resistant / Q000188:drug therapy; D006801:Humans; D007649:Ketamine / Q000037:antagonists & inhibitors / Q000627:therapeutic use*
D000928:Antidepressive Agents; D001569:Benzodiazepines; D007649:Ketamine